CRAF R391W is a melanoma driver oncogene

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Melanoma often harbors driver mutations in BRAF, NRAS, GNA11, or GNAQ.
• A subset of melanomas lacks these known oncogenic drivers, necessitating the identification of alternative mutations.

Purpose of the Study:

• To identify novel driver mutations in melanomas lacking common oncogenic alterations.
• To investigate the functional role of CRAF R391W as a potential oncogene in melanoma.

Main Methods:

• Establishment and characterization of a novel melanoma cell line.
• RNA sequencing (RNA-seq) for mutation analysis.
• CRNA knockdown and reconstitution experiments.
• In vitro kinase assays and NIH3T3 transformation assays.

Main Results:

• The novel melanoma cell line exhibited a signaling profile resembling BRAF-mutants but was resistant to vemurafenib.
• RNA-seq identified homozygous, overexpressed CRAF R391W as the driver mutation.
• CRNA knockdown, but not BRAF knockdown, affected melanoma cell signaling.
• CRAF R391W, unlike wild-type CRAF, transformed NIH3T3 cells, increased kinase activity, induced MAP kinase signaling, and conferred vemurafenib resistance.

Conclusions:

• CRAF R391W acts as a bona fide oncogene in melanomas that are wild-type for BRAF, NRAS, GNAQ, and GNA11.
• CRAF dimerization is crucial for its oncogenic signaling activity.
• This finding identifies CRAF as a potential therapeutic target for a subset of melanomas.